https://biotechmorning.com/news/parabilis-medicines-ipo-800m-startup Biotech Morning en 2026-06-09T14:29:17.246Z The $800M Startup That Still Needs Half a Billion More https://biotechmorning.com/news/astrazeneca-oral-glp1-comeback Biotech Morning en 2026-06-09T14:28:28.867Z AstraZeneca Wants Into the GLP-1 Business. And the Pill They're Betting On Just Posted Real Data. https://biotechmorning.com/news/jnj-billion-dollar-firefly-bio-dac-acquisition Biotech Morning en 2026-06-09T14:27:32.654Z J&J Just Paid $1 Billion for a Drug That Doesn't Exist Yet https://biotechmorning.com/news/gsk-nuvalent-10-billion-oncology-acquisition Biotech Morning en 2026-06-09T14:26:41.471Z GSK Just Wrote a $10.6 Billion Check for Two Drugs That Don't Exist Yet https://biotechmorning.com/news/hympavzi-fda-expansion-pediatric-hemophilia-inhibitors Biotech Morning en 2026-06-09T14:25:50.181Z The Shot That Could Replace IV Drips for Kids With Hemophilia https://biotechmorning.com/news/tango-therapeutics-pancreatic-cancer-breakthrough Biotech Morning en 2026-06-09T14:24:58.534Z The Cancer That Kills Almost Everyone Just Met Its Worst Nightmare https://biotechmorning.com/news/venglustat-brain-barrier-gaucher-type-3 Biotech Morning en 2026-06-09T14:24:03.894Z The Pill That Crosses the Brain's Toughest Bouncer https://biotechmorning.com/news/afrezza-inhaled-insulin-pediatric-approval Biotech Morning en 2026-06-09T14:23:12.570Z The Insulin That Kids Don't Have to Stab Themselves With https://biotechmorning.com/news/hiv-pill-came-back-from-the-dead Biotech Morning en 2026-06-09T14:22:15.977Z The HIV Pill That Came Back From the Dead https://biotechmorning.com/news/boehringer-survodutide-obesity-drug-ada-2026-competitive-concerns Biotech Morning en 2026-06-08T14:27:36.618Z Boehringer's Obesity Drug Just Hit a Wall. It's Called Tirzepatide. https://biotechmorning.com/news/roche-nurix-btk-degrader-deal Biotech Morning en 2026-06-08T14:26:44.554Z Roche Just Paid $700 Million for a Drug That Destroys Proteins Instead of Blocking Them https://biotechmorning.com/news/gsk-44-million-fibrosis-regression-engitix Biotech Morning en 2026-06-08T14:25:49.536Z GSK's £44 Million Bet That Scar Tissue Can Be Unscared https://biotechmorning.com/news/lilly-202m-engage-biologics-tethosome-no-drug Biotech Morning en 2026-06-08T14:24:58.643Z Lilly Just Paid $202M for a Company With No Drug. Here's Why. https://biotechmorning.com/news/car-t-liver-cancer-oricell-gpc3-hcc Biotech Morning en 2026-06-08T14:24:07.612Z CAR-T Just Broke Into the Liver Cancer Club https://biotechmorning.com/news/antag-therapeutics-gipr-antagonist-obesity Biotech Morning en 2026-06-08T14:23:09.996Z This Tiny Danish Biotech Is Betting Against the Hottest Drug Strategy in Medicine https://biotechmorning.com/news/incyte-2-billion-bet-von-willebrand-disease Biotech Morning en 2026-06-08T14:22:16.523Z Incyte Just Bet $2 Billion on a Disease You've Probably Never Heard Of